Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies that guide T cells to target chronic infectious diseases and autoimmunity. Their therapies aim to induce sustained reductions in viral antigens, improving patient outcomes in conditions such as chronic hepatitis B and human papillomavirus-related lesions.
Funding
$168M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MGFounders
Product
Problem
Chronic infectious diseases and autoimmune disorders often evade the body's natural defenses, leading to persistent infections and immune system dysfunction. Current treatments may not effectively target the underlying cause of these conditions, resulting in limited long-term benefits for patients.
Solution
Barinthus Biotherapeutics develops antigen-specific immunotherapies designed to redirect T cells to precisely target and eliminate cells affected by chronic infections and autoimmunity. These immunotherapies aim to induce sustained reductions in viral antigens and modulate the immune response, leading to improved patient outcomes. By guiding T cells to specific disease targets, the therapies offer a more focused and potentially curative approach compared to traditional treatments. The company's pipeline includes therapies targeting chronic hepatitis B and human papillomavirus-related lesions.
Target Audience
The primary target audience includes patients suffering from chronic infectious diseases like chronic hepatitis B and human papillomavirus, as well as individuals with autoimmune disorders.
Features
- Antigen-specific immunotherapy approach for targeted T-cell redirection
- Development of therapies for chronic hepatitis B (HBV)
- Development of therapies for human papillomavirus (HPV)-related lesions
- Focus on inducing sustained reductions in viral antigens
- Modulation of the immune response to address autoimmune disorders